On September 17, the FDA approved cariprazine (Vraylar) for the treatment of schizophrenia and bipolar disorder. There’s already some buzz about whether this medication has advantages over other atypicals for treating negative symptoms of schizophrenia.

On July 10, the U.S. Food and Drug Administration (FDA) approved Otsuka and Lundbeck’s Rexulti (brexpiprazole) for schizophrenia and as an add-on to antidepressants for adults with depression. As the name suggests, it’s chemically and structurally related to aripiprazole (Abilify).

A powdered alcohol product that users will mix with water or other liquids has been approved for sale in the US. The Alcohol and Tobacco Tax and Trade Bureau, part of the US Treasury Department, approved labels for the powdered alcohol, called Palcohol. The powdered product would be mixed like an instant tea or lemonade.

The anti-smoking drug Chantix (varenicline) may affect how people respond to alcohol, according to an FDA warning.

In March 2015, the US Food and Drug Administration (FDA) approved Actavis’ asenapine (Saphris) for the acute treatment of manic or mixed episodes associated with bipolar disorder in kids between 10 and 17 years.

Lisdexamfetamine (Vyvanse), a stimulant approved for treating kids and adults with ADHD, is the first drug approved by the US Food and Drug Administration (FDA) for treating adults with binge-eating disorder (BED).

Drinking too much alcohol in a short period of time is proving deadly for many Americans.

In December 2014, the US Food and Drug Administration (FDA) issued a safety announcement warning that the antipsychotic drug ziprasidone (Geodon) has been associated with a rare but potentially fatal skin reaction.

There’s a new drug in the arsenal to fight obesity.

Whether generics are really therapeutically equivalent to branded versions of drugs has long been controversial.